• About Us
  • Copyright Policy
  • Disclaimer
  • Authors
  • Career
  • Contact Us
Assamese |   Bengali |  
Sunday, January 17, 2021
NORTHEAST NOW
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion
No Result
View All Result
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion
No Result
View All Result
NORTHEAST NOW
Assamese
Home Health

Oxford University to begin human trials of COVID-19 vaccine from Thursday

NE NOW NEWS by NE NOW NEWS
GUWAHATI , April 22, 2020 1:31 pm
COVID-19 Vaccine

Representative photo. Image credit - www.pmlive.com

Share on FacebookShare on Twitter

The UK government on Tuesday said that the human trials of a potential vaccine developed at the Oxford University will begin from Thursday.

UK Health Secretary Matt Hancock said the government will provide 20 million pounds to the Oxford research team to help fund their clinical trials, with a further 22.5 million pounds for researchers at Imperial College London.

“The first human trials for vaccines begin in the UK on Thursday. We’re giving the 2 leading UK vaccine teams at Oxford & Imperial all the support they need to make it happen,” Hancock also said in a tweet.

The potential vaccine is an adenovirus vaccine vector (ChAdOx1) and was developed at Oxford’s Jenner Institute, the university had said in a statement earlier.

“It was chosen as the most suitable vaccine technology for a SARS-CoV-2 (COVID-19) vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual,” it added.

The university also stated that the potential vaccine is safer to give to children, the elderly and anyone with a pre-existing condition such as diabetes.

“Adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of subjects, from 1 week to 90 years of age, in vaccines targeting over 10 different diseases,” it added.

Tags: COVID19
Trouble mounts for WhatsApp, phone numbers of users found on Google search: Reports

Trouble mounts for WhatsApp, phone numbers of users found on Google search: Reports

Dense fog engulfs Assam, Meghalaya and Tripura

Dense fog engulfs Assam, Meghalaya and Tripura

Syed Mushtaq Ali Trophy: Riyan Parag’s all-round performance propel Assam to 13-run win against Bengal

Syed Mushtaq Ali Trophy: Riyan Parag’s all-round performance propel Assam to 13-run win against Bengal

Manipur: Schools, colleges to reopen from January 27

Manipur: Schools, colleges to reopen from January 27

NORTHEAST NOW

Northeast Now is a multi-app based hyper-regional bilingual news portal. Led by a group of professionals, the digital news platform covers every inch of the eight states of northeast India and the five neighbouring countries. It is the first of its kind new media initiative in the northeast, and is based in Guwahati. As the political dynamics in the northeast is intricate and fluid, Northeast Now is always politically neutral.

 
Our Properties
 
  • NORTHEAST NOW ASSAMESE
  • NORTHEAST JOBS
  • NORTHEAST TENDERS
  • INNFINITY
  • About Us
  • Copyright Policy
  • Disclaimer
  • Authors
  • Career
  • Contact Us

© 2019 - Maintained by EZEN Software & Technology Pvt. Ltd

No Result
View All Result
  • HOME
  • NORTH EAST
    • Assam
    • Meghalaya
    • Tripura
    • Mizoram
    • Manipur
    • Nagaland
    • Arunachal
    • Sikkim
  • Neighbours
    • Nepal
    • Bhutan
    • China
    • Myanmar
    • Bangladesh
  • Business
  • Entertainment
  • Sports
  • Environment
  • Citizen Journalists
  • Opinion

© 2019 - Maintained by EZEN Software & Technology Pvt. Ltd